Lapatinib plus Capecitabine versus Trastuzumab plus Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer with Central Nervous System Metastases for Patients Currently or Previously Treated with Trastuzumab (LANTERN): a Phase II Randomised Trial-Reference-Cited by-同舟云学术

Lapatinib plus Capecitabine versus Trastuzumab plus Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer with Central Nervous System Metastases for Patients Currently or Previously Treated with Trastuzumab (LANTERN): a Phase II Randomised Trial

Published:2020-10 Issue:10 Volume:32 Page:656-664
ISSN:0936-6555
Container-title:Clinical Oncology
language:en
Short-container-title:Clinical Oncology

Author:

Seligmann J.F.,Wright-Hughes A.,Pottinger A.,Velikova G.,Oughton J.B.,Murden G.,Rizwanullah M.,Price C.,Passant H.,Heudtlass P.,Marshall H.,Johnston S.,Dodwell D.

Funder

National Institute for Health Research Cancer Research Network

Cancer Research UK

GSK

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology

Reference28 articles.

1. ERBB receptors and cancer: the complexity of targeted inhibitors;Hynes;Nat Rev Cancer,2005

2. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer;Romond;New Engl J Med,2005

3. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;New Engl J Med,2001